Skip to main content

Tryp Therapeutics Inc. (TRYPF)

New York Stock Exchange Healthcare BiotechnologyView data quality →
31.6Poor

ValueMarkers Composite Index

Top 1%#44,472 of 44,707

DCF data not available

Piotroski
2/9
Weak
Beneish
-
Altman
-71.46
Distress
DCF Value
-
N/A
ROIC
3.6%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Tryp Therapeutics Inc. (TRYPF) — VMCI valuation read

Composite valuation read on TRYPF: VMCI 32/100 against a Healthcare sector median of 50. The 18-point below-median print is the headline number for Tryp Therapeutics Inc., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for TRYPF: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on TRYPF: TRYPF trades at 25.0x earnings, 39% above the Healthcare median of 18.0x; ROIC of 13.0% sits 3.0pp above the Healthcare median (10.0%); net debt to EBITDA of 2.4x is the rate-sensitivity line to watch. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

TRYPF rose 2.6% over the trailing 7 days, with a +3.0% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in TRYPF’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.